The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes

Diabetologia

Volumn 56, Issue 10, 2013, Pages 2308-2317

  Cherney, David Z I ^a   Reich, Heather N ^a   Scholey, James W ^a   Daneman, Denis ^b   Mahmud, Farid H ^b   Har, Ronnie L H ^a   Sochett, Etienne B ^b  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Clamped hyperglycaemia; Type 1 diabetes mellitus; Urine cytokines chemokines; Urine proteomic analysis

Indexed keywords

ALISKIREN; ALPHA2 INTERFERON; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR 2; MACROPHAGE DERIVED CHEMOKINE;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE MARKER; DRUG EFFICACY; FEMALE; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BLOOD FLOW; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; URINALYSIS; URINE LEVEL;

ADULT; AMIDES; CHEMOKINES; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; FUMARATES; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; P-AMINOHIPPURIC ACID; PROTEOMICS; YOUNG ADULT;

EID: 84890119454     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-3000-3     Document Type: Article

References (50)

1. Brownlee M, Hirsch IB (2006) Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA 295:1707-1708
2. Gordin D, Ronnback M, Forsblom C, Heikkila O, Saraheimo M, Groop PH (2007) Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. Diabetologia 50:1808-1814
3. Esposito K, Nappo F, Marfella R et al (2002) Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106:2067-2072
4. Stegenga ME, van der Crabben SN, Dessing MC et al (2008) Effect of acute hyperglycaemia and/or hyperinsulinaemia on proinflammatory gene expression, cytokine production and neutrophil function in humans. Diabet Med 25:157-164
5. Gordin D, Forsblom C, Ronnback M et al (2008) Acute hyperglycaemia induces an inflammatory response in young patients with type 1 diabetes. Ann Med 1-7
6. Miller JA (1999) Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 10:1778-1785
7. Cherney DZ, Scholey JW, Miller JA (2008) Insights into the regulation of renal hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4:280-290
8. Cherney DZ, Miller JA, Scholey JW et al (2008) The effect of cyclooxygenase-2 inhibition on renal hemodynamic function in humans with type 1 diabetes. Diabetes 57:688-695
9. Cherney DZI, Scholey JW, Sochett EB (2013) Sex differences in renal responses to hyperglycemia, L-arginine and L-NMMA in humans with uncomplicated type 1 diabetes mellitus. Diabetes Care 36:1290-1296
10. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN (2011) The acute effect of clamped hyperglycemia on the urinary excretion of inflammatory cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes Care 34:177-180
11. Cherney DZ, Scholey JW, Daneman D et al (2012) Urinary markers of renal inflammation in adolescents with type 1 diabetes mellitus and normoalbuminuria. Diabet Med 29:1297-1302
12. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E et al (2012) Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol 302:F647-F657
13. Merchant ML, Perkins BA, Boratyn GM et al (2009) Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 20:2065-2074
14. Nguyen TQ, Tarnow L, Andersen S et al (2006) Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care 29:83-88
15. Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26:2421-2425
16. Mauer M, Zinman B, Gardiner R et al (2009) Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40-51
17. Cherney DZ, Scholey JW, Jiang S et al (2012) The effect of direct renin inhibition alone and in combination with ACE inhibition on endothelial function, arterial stiffness, and renal function in type 1 diabetes. Diabetes Care 35:2324-2330
18. Cherney DZ, Lai V, Scholey JW, Miller JA, Zinman B, Reich HN (2010) Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes: a pilot study. Diabetes Care 33:361-365
19. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, Miller JA (2006) Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. J Am Soc Nephrol 17:1703-1709
20. Lambers Heerspink HJ, Holtkamp FA, Parving HH et al (2012) Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 82:330-337
21. Duprez DA (2006) Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: a clinical review. J Hypertens 24:983-991
22. Song JH, Cha SH, Lee HJ et al (2006) Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease. Nephrol Dial Transplant 21:683-689
23. Esmatjes E, Flores L, Inigo P, Lario S, Ruilope LM, Campistol JM (2001) Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 16(Suppl 1):90-93
24. Song JH, Cha SH, Hong SB, Kim DH (2006) Dual blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens 24(Suppl):S101-S106
25. Song JH, Lee SW, Suh JH et al (2003) The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 60:318-326
26. Cherney DZ, Reich HN, Jiang S et al (2012) Hyperfiltration and the effect of nitric oxide inhibition on renal and endothelial function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol Regul Integr Comp Physiol 303:R710-R718
27. Davidson WD, Sackner MA (1963) Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 62:351-356
28. Jung K, Klotzek S, Schulze BD (1990) Refinements of assays for low concentrations of inulin in serum. Nephron 54:360-361
29. Florijn KW, Barendregt JN, Lentjes EG et al (1994) Glomerular filtration rate measurement by 'single-shot' injection of inulin. Kidney Int 46:252-259
30. Cherney DZ, Miller JA, Scholey JW et al (2010) Renal hyperfiltration is a determinant of endothelial function responses to cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care 33:1344-1346
31. Cherney DZ, Konvalinka A, Zinman B et al (2009) Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study. Diabetes Care 32:91-93
32. Har R, Scholey JW, Daneman D et al (2013) The effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56:1166-1173
33. Touyz RM, Tabet F, Schiffrin EL (2003) Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 30:860-866
34. Touyz RM (2005) Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 14:125-131
35. Ruperez M, Ruiz-Ortega M, Esteban V et al (2003) Angiotensin II increases connective tissue growth factor in the kidney. Am J Pathol 163:1937-1947
36. Duprez DA (2004) Angiotensin II, platelets and oxidative stress. J Hypertens 22:1085-1086
37. Chobanian AV, Haudenschild CC, Nickerson C, Drago R (1990) Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15:327-331
38. Schieffer B, Bunte C, Witte J et al (2004) Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol 44:362-368
39. Proudfoot JM, Croft KD, Puddey IB, Beilin LJ (2003) Angiotensin II type 1 receptor antagonists inhibit basal as well as low-density lipoprotein and platelet-activating factor-stimulated human monocyte chemoattractant protein-1. J Pharmacol Exp Ther 305:846-853
40. Fliser D, Buchholz K, Haller H (2004) Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110:1103-1107
41. Tashiro K, Koyanagi I, Saitoh A et al (2002) Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 16:1-4
42. Pelikanova T, Simkova R, Tesar V, Jirsa M (2003) Effect of acute hyperglycaemia on selected plasma and urinary cytokine antagonists in type 1 diabetes mellitus. Diabetologia 46:470-474
43. Riser BL, Cortes P, Heilig C et al (1996) Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am J Pathol 148:1915-1923
44. Hernandez-Presa M, Bustos C, Ortego M et al (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532-1541
45. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK (2008) Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation 117:3199-3205
46. Hollenberg NK, Fisher ND, Nussberger J, Moukarbel GV, Barkoudah E, Danser AH (2011) Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients? J Hypertens 29:2454-2461
47. Vallon V, Thomson SC (2012) Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol 74:351-375
48. Vallon V, Blantz RC, Thomson S (2003) Glomerular hyperfiltration and the salt paradox in early [corrected] type 1 diabetes mellitus: a tubulo-centric view. J Am Soc Nephrol 14:530-537
49. Miller JA (1997) Renal responses to sodium restriction in patients with early diabetes mellitus. J Am Soc Nephrol 8:749-755
50. Thomson SC, Rieg T, Miracle C et al (2012) Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 302:R75-R83